ArticleAmerican journal of translational research2020
DANCR: an emerging therapeutic target for cancer.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Regulatory role of lncRNA DANCR in osteogenic differentiation of bone marrow mesenchymal stem cells through targeting the miR-19a-3p/PTEN/AKT/mTOR pathway.In vitro cellular & developmental biology. Animal · 2026Article
- Review
- The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.Combinatorial chemistry & high throughput screening · 2024Review
- Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy.ACS omega · 2022Article
- Expression ofMolecular medicine reports · 2022Article
- The role of PI3K/AKT signaling pathway in gallbladder carcinoma.American journal of translational research · 2022Review
- Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.Frontiers in immunology · 2022Article
- The Effect of miR-145-5p, DANCR and NRAS Expression Levels on the Survival Rate of Colorectal Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Long noncoding RNA SNHG4: a novel target in human diseases.Cancer cell international · 2021Review
- LINC00261: a burgeoning long noncoding RNA related to cancer.Cancer cell international · 2021Review
- Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets.Frontiers in oncology · 2021Article
- Lidocaine and Bupivacaine Downregulate MYB andFrontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of long non-coding RNAs (lncRNAs) revolutionized the current framework for understanding the molecular mechanisms of tumorigenesis and stimulated the search for targeted cancer treatments. Among lncRNAs, differentiation antagonizing non-protein-coding RNA (DANCR) is a newly identified oncogenic gene that is upregulated in diverse cancer types and has a critical role in cancer progression. Herein, we summarize current knowledge regarding DANCR regulatory functions related to cancer cell proliferation, invasion, metastasis, and chemo-resistance. We also synthesize the effects of DANCR on cancer stemness features, the epithelial-mesenchymal transition (EMT), and angiogenesis, which are essential for the progression of malignant cancer cells. Mechanically, the interaction between DANCR and its targets including microRNAs (miRNAs), mRNAs, and proteins are also elucidated. Finally, we propose DANCR-based therapeutic approaches to provide novel insights about cancer treatment.
Indexed as
Identifiers
32774756PMC7407722W3049009587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.